Related Experiment Videos
Multicentric reticulohistiocytosis
Francesco Trotta1, Gabriella Castellino, Andrea Lo Monaco
1Sezione di Reumatologia, Dipartimento di Medicina Clinica e Sperimentale, Università degli Studi di Ferrara, Corso della Giovecca 203, 44100 Ferrara, Italy. trf@unife.it
Best Practice & Research. Clinical Rheumatology
|September 30, 2004
Summary
Multicentric reticulohistiocytosis (MR) is a rare disease affecting joints and skin, often linked to cancer. Early diagnosis and aggressive immunosuppressive treatment are crucial for managing this severe condition.
Area of Science:
- Rheumatology
- Dermatology
- Oncology
Background:
- Multicentric reticulohistiocytosis (MR) is an uncommon systemic disorder.
- Characterized by joint and skin manifestations, predominantly in middle-aged women.
- Diagnosis requires histological confirmation of characteristic mononuclear histiocytes and multinucleated giant cells.
Purpose of the Study:
- To highlight the diagnostic challenges and clinical course of MR.
- To emphasize the association between MR and malignancy.
- To discuss current and emerging treatment strategies for MR.
Main Methods:
- Review of clinical presentations and diagnostic criteria for MR.
- Emphasis on differential diagnosis from common rheumatic disorders.
- Discussion of histopathological findings.
Main Results:
- MR can present with arthralgia mimicking other rheumatic diseases, delaying diagnosis.
- A significant association exists between MR and underlying malignancy, necessitating thorough oncological screening.
- The disease can progress to severe destructive arthropathy and disfiguring skin lesions.
Conclusions:
- Early and accurate diagnosis of MR is critical, often requiring a multidisciplinary approach.
- Vigilant exclusion of malignancy is paramount in MR patients.
- Aggressive immunosuppressive therapy, potentially including anti-TNF-alpha agents and alendronate, is recommended for severe cases.